Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACKLE-IT
NCT06474273Phase 3Recruiting
- Sponsor
- University of Sydney
- Start
- Mar 2026
- Primary completion
- Jun 2030
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 3 trial of methylprednisolone injection, prednisone in Acute T-cell-mediated Rejection (aTCMR), sponsored by University of Sydney. Started Mar 2026; status: recruiting.
02
Drugs
methylprednisolone injectionprednisone
03
Conditions
Acute T-cell-mediated Rejection (aTCMR)
Beyond the preview
Go deeper on NCT06474273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06474273.